中文摘要：

目的：探讨紫杉醇联合地西他滨对晚期胃癌患者血清癌胚抗原（CEA）、糖类抗原19-9（CA19-9）、糖类抗原72-4（CA72-4）水平的影响。方法：收集2013年10月-2015年1月于我院住院治疗的晚期胃癌患者122例,随机分为实验组和对照组。实验组患者给予紫杉醇和地西他滨化疗,对照组患者给予紫杉醇和安慰剂化疗。观察并比较两组患者治疗前后卡氏积分、血常规、血尿素氮、肌酐、转氨酶含量以及血清CA199、CEA及CA724水平的变化情况。结果：治疗后,两组患者的卡氏积分均较治疗前明显升高,血清CEA、CA19-9、CA72-4水平均较治疗前显著降低,且实验组的卡氏积分显著高于对照组,血清CEA、CA19-9、CA72-4水平明显低于对照组,差异均具有统计学意义（P〈0.05）。治疗前后,两组患者的白细胞、血红蛋白及血小板水平比较均无统计学差异（P〉0.05）。结论：紫杉醇联合地西他滨能有效降低晚期胃癌患者血清CEA、CA19-9、CA72-4水平,并提高患者的生存质量,且安全性较好。

英文摘要：

Objective： To investigate the effect of paclitaxel combined with decitabine on the changes of serum CEA, CA19-9 and CA72-4 levels in patients with advanced gastric cancer. Methods： 122 patients with advanced gastric cancer who were treated in our hospital from October 2013 to January 2015 were selected and randomly divided into the control group and the experimental group. The patients in the experimental group were treated with paclitaxel and decitabine chemotherapy, while the patients in control group were treated with paclitaxel and placebo. Then the Karn of sky score, blood routine, blood urea nitrogen, creatinine, ALT, levels of CEA, CA724 and CA199 in serum of patients were observed and compared between two groups before and after the treatment. Results： Compared with before treatment, the Karnofsky score in the both groups increased after the treatment, and the serum levels of CEA, CA724 and CA199 decreased （P〈0.05）. Compared with the control group after treatment, the Karaofsky score was higher, and the serum levels of CEA, CA724 and CA199 were lower in the experimental group （P〈0.05）. Conclusion： Paclitaxel combined with decitabine could effectively reduce the serum CEA, CA19-9 and CA72-4 levels and improve the quality of life of patients with advanced gastric cancer.